Open Access

REVIEW

SHUBHRA CHANDRA^1,2, JENNIFER C. WILSON^1,2, DAVID GOOD³, MING Q. WEI^1,2,*
Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More >

Graphic Abstract

View

338

Download

50

Open Access

ARTICLE

MEHRSA JALALIZADEH^1,#, HEVELINE RAYANE MOURA ROESCH^1,#, FERNANDO KORKES², QUOC DIEN-TRINH³, LEONARDO OLIVEIRA REIS^1,4,*
Oncology Research, Vol.32, No.10, pp. 1565-1573, 2024, DOI:10.32604/or.2024.052179
Abstract Objectives: The Brazilian Unified Health System (Sistema Único de Saúde−SUS) is the universal public healthcare system of Brazil that maintains a nationwide database of its patients. Our primary objective was to analyze regional and temporal trends, while our secondary goal was to establish correlations between states’ health economy status and their prostate cancer (PCa) epidemiology. Methods: We analyzed Brazil’s nationwide data on prostate cancer (PCa) incidence, mortality, and care gathered between 2013 and 2021 by the Information Technology Department of SUS (DATA-SUS), updated monthly using the International Classification of Diseases (ICD-10) code. Results: In the period,… More >

View

357

Download

62

Open Access

ARTICLE

EGOR V. BATOROV^1,2,*, ALISA D. INESHINA², TATIANA A. ARISTOVA³, VERA V. DENISOVA³, SVETLANA A. SIZIKOVA³, DARIA S. BATOROVA³, GALINA Y. USHAKOVA³, EKATERINA Y. SHEVELA¹, ELENA R. CHERNYKH¹
Oncology Research, Vol.32, No.10, pp. 1575-1587, 2024, DOI:10.32604/or.2024.047893
Abstract Background: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules. Methods: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow… More >

View

311

Download

48

Open Access

REVIEW

SUBHAYAN SUR^1,*, DIMPLE DAVRAY², SOUMYA BASU¹, SUPRIYA KHEUR³, JAYANTA KUMAR PAL¹, SHUCHI NAGAR², AVINASH SANAP³, BHIMAPPA M. RUDAGI³, SAMIR GUPTA⁴
Oncology Research, Vol.32, No.10, pp. 1589-1612, 2024, DOI:10.32604/or.2024.052120
Abstract Oral squamous cell carcinoma (OSCC) is one of the most prevalent forms of head and neck squamous cell carcinomas (HNSCC) with a poor overall survival rate (about 50%), particularly in cases of metastasis. RNA-based cancer biomarkers are a relatively advanced concept, and non-coding RNAs currently have shown promising roles in the detection and treatment of various malignancies. This review underlines the function of long non-coding RNAs (lncRNAs) in the OSCC and its subsequent clinical implications. LncRNAs, a class of non-coding RNAs, are larger than 200 nucleotides and resemble mRNA in numerous ways. However, unlike mRNA,… More >

View

319

Download

60

Open Access

REVIEW

WEIGANG XIU^1,#, XINGYU LIU^1,2,#, KAIXIN HU^1,2, QIN ZHANG^3,*, HUASHAN SHI^4,*
Oncology Research, Vol.32, No.10, pp. 1613-1621, 2024, DOI:10.32604/or.2024.047933
（This article belongs to the Special Issue: Metabolism of Cancer Cells and Immune Cells: A Balancing Action for Cancer Immunotherapy)
Abstract Elevated serum cholesterol metabolism is associated with a reduced risk of lung cancer. Disrupted cholesterol metabolism is evident in both lung cancer patients and tumor cells. Inhibiting tumor cell cholesterol uptake or biosynthesis pathways, through the modulation of receptors and enzymes such as liver X receptor and sterol-regulatory element binding protein 2, effectively restrains lung tumor growth. Similarly, promoting cholesterol excretion yields comparable effects. Cholesterol metabolites, including oxysterols and isoprenoids, play a crucial role in regulating cholesterol metabolism within tumor cells, consequently impacting cancer progression. In lung cancer patients, both the cholesterol levels in the… More >

View

527

Download

117

Open Access

ARTICLE

YI LI¹, TIANYI WANG¹, HAORAN DING¹, SHIYONG ZHUANG¹, XIAOBO DAI¹, BING YAN^1,2,*
Oncology Research, Vol.32, No.10, pp. 1623-1635, 2024, DOI:10.32604/or.2024.048191
Abstract Background: Oral cancer, a malignancy that is prevalent worldwide, is often diagnosed at an advanced stage. MicroRNAs (miRNAs) in circulating exosomes have emerged as promising cancer biomarkers. The role of miRNA let-7c-5p in oral cancer remains underexplored, and its potential involvement in tumorigenesis warrants comprehensive investigation. Methods: Serum samples from 30 patients with oral cancer and 20 healthy controls were used to isolate exosomes and quantify their RNA content. Isolation of the exosomes was confirmed through transmission electron microscopy. Quantitative PCR was used to assess the miRNA profiles. The effects of let-7c-5p and TAGLN overexpression… More >

View

476

Download

87

Open Access

ARTICLE

ZHIGUO WANG^1,2,#, KUNLIN LI^2,#, CONGHUA LU², MINGXIA FENG², CAIYU LIN², GUOFANG YIN¹, DAN LUO¹, WENYI LIU³, KAIYU JIN⁴, YUANYAO DOU², DI WU², JIE ZHENG², KEJUN ZHANG⁵, LI LI^2,*, XIANMING FAN^1,*
Oncology Research, Vol.32, No.10, pp. 1637-1648, 2024, DOI:10.32604/or.2024.052664
（This article belongs to the Special Issue: New Era in Cancer Treatment: Advances in Targeted and Pharmacological Therapies with the Subtle Integration of Multi-Omics)
Abstract Background: Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in serine/threonine kinase 11 (STK11) mutant non-small cell lung cancer (NSCLC) through an axis inhibition protein 1 (AXIN1)-dependent manner. However, the alterations of tumor metabolism and metabolites upon metformin administration remain unclear. Methods: We performed untargeted metabolomics using liquid chromatography (LC)-mass spectrometry (MS)/MS system and conducted cell experiments to verify the results of bioinformatics analysis. Results: According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database, most… More >

Graphic Abstract

View

37

Download

22

Open Access

REVIEW

YUN WANG¹, XIAOJIANG LI², DALONG LIU², ZHIFENG WANG³, JICHEN XIA⁴, LIJUN WANG⁵, XUDONG ZHANG^6,*
Oncology Research, Vol.32, No.10, pp. 1649-1660, 2024, DOI:10.32604/or.2024.043482
Abstract Exosomes, minute vesicles ubiquitously released by diverse cell types, serve as critical mediators in intercellular communication. Their pathophysiological relevance, especially in malignancies, has garnered significant attention. A meticulous exploration of the exosomal impact on cancer development has unveiled avenues for innovative and clinically valuable techniques. The cargo conveyed by exosomes exerts transformative effects on both local and distant microenvironments, thereby influencing a broad spectrum of biological responses in recipient cells. These membrane-bound extracellular vesicles (EVs) play a pivotal role in delivering bioactive molecules among cells and organs. Cellular and biological processes in recipient cells, ranging… More >

Graphic Abstract

View

453

Download

70

Open Access

REVIEW

FEI CHU¹, KAI TONG¹, XIANG GU¹, MEI BAO¹, YANFEN CHEN¹, BIN WANG², YANHUA SHAO¹, LING WEI^1,*
Oncology Research, Vol.32, No.10, pp. 1661-1671, 2024, DOI:10.32604/or.2024.048287
Abstract Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively More >

Graphic Abstract

View

580

Download

92

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1673-1674, 2024, DOI:10.32604/or.2024.056900
Abstract This article has no abstract. More >

View

21

Download

17

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1675-1676, 2024, DOI:10.32604/or.2024.056889
Abstract This article has no abstract. More >

View

92

Download

21

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1677-1678, 2024, DOI:10.32604/or.2024.056891
Abstract This article has no abstract. More >

View

84

Download

20

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1679-1680, 2024, DOI:10.32604/or.2024.056894
Abstract This article has no abstract. More >

View

78

Download

20

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1681-1682, 2024, DOI:10.32604/or.2024.056898
Abstract This article has no abstract. More >

View

94

Download

21

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1683-1684, 2024, DOI:10.32604/or.2024.056899
Abstract This article has no abstract. More >

View

89

Download

26

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1685-1686, 2024, DOI:10.32604/or.2024.056901
Abstract This article has no abstract. More >

View

89

Download

23

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1687-1688, 2024, DOI:10.32604/or.2024.056903
Abstract This article has no abstract. More >

View

101

Download

25

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1689-1690, 2024, DOI:10.32604/or.2024.056905
Abstract This article has no abstract. More >

View

93

Download

24

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1691-1692, 2024, DOI:10.32604/or.2024.056908
Abstract This article has no abstract. More >

View

101

Download

26

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1693-1694, 2024, DOI:10.32604/or.2024.056909
Abstract This article has no abstract. More >

View

95

Download

27

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1695-1696, 2024, DOI:10.32604/or.2024.056913
Abstract This article has no abstract. More >

View

100

Download

26

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1697-1698, 2024, DOI:10.32604/or.2024.056918
Abstract This article has no abstract. More >

View

106

Download

31

Open Access

RETRACTION

Oncology Research, Vol.32, No.10, pp. 1699-1700, 2024, DOI:10.32604/or.2024.056919
Abstract This article has no abstract. More >

View

114

Download

29